UTAH MEDICAL PRODUCTS INC — Form 8-K

Utah Medical Products reported 3Q 2026 revenues of $8.621M, down 12.1% YoY ($1.191M decline). Two major customers—PendoTECH (biopharm OEM) and China BPM distributor—generated zero 2026 sales vs. $491K in 3Q 2025 combined; together they accounted for $2.419M of the $3.602M nine-month revenue decline. Filshie Clip System sales fell 32.7% in 3Q. Offsetting: Orion Medical acquisition (UK, $5.0M cash paid, added $619K in 3Q sales) and new biopharm customers ($327K YTD). Despite lower sales, 3Q net income rose 5.9% to $2.787M (to $0.876 EPS) due to completed Femcare amortization ($511K benefit) and lower litigation expense ($186K improvement). Company projects full-year 2026 sales decline near 7% vs. 12% YTD actual. Cash position $85.2M (essentially flat after dividends, buybacks, Orion acquisition).